| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04258150 Details | 2022-03-31 Interventional | 2 | 26 | Ipilimumab Nivolumab Pancreatic Neop… Pancreatic Canc… | primary endpoint was not met - | |||
| NCT03294694 Details | 2022-03-31 Interventional | 1 | 33 | Fulvestrant Spartalizumab Breast Neoplasm… Carcinoma, Ovar… Ovarian Neoplas… HER2-Negative B… Metastatic Epit… Metastatic Horm… | Safety Implications - | |||
| NCT03235986 2016-004547-36 Details | 2022-03-31 Interventional | 2 | [1 Refs] | 166 | Poractant alfa Hyaline Membran… Respiratory Dis… Respiratory Dis… Syndrome Neonatal Respir… | Change in the benefit-risk balance - | ||
| NCT02838745 Details | 2022-03-31 Interventional | 1 | 7 | Pemetrexed Mesothelioma Mesothelioma, M… | Change in research plan. - | |||
| NCT02419664 2010-020482-24 Details | 2022-03-31 Interventional | 3 | 22 | Edotreotide Pituitary Disea… Pituitary Neopl… Pituitary Tumou… | The hypothesis we had that we could predict the growth rate from PET uptake could not be
confirmer and 3-year follow up was no longer considered motivated - | |||
| NCT00015002 Details | 2022-03-31 Interventional | 3 | [5 Refs] | 486 | Betamethasone Pregnancy Compl… Complications, … | Concerns regarding neonatal data - | ||
| NCT04974996 Details | 2022-03-29 Interventional | 1 | 0 | Cyclophosphamid… Doxorubicin Loncastuximab t… Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | Decision to not proceed with study. - | |||
| NCT04754815 Details | 2022-03-29 Interventional | 2 | 0 | Albumin-Bound P… Paclitaxel Pembrolizumab Pemetrexed Carcinoma, Non-… Lung Neoplasms Advanced Lung N… Non Small Cell … PD-L1 Gene Muta… | Logistical challenges primarily due to COVID led to delay in starting the study and now is not
felt to be clinically relevant. - | |||
| NCT04500418 2020-001493-29 Details | 2022-03-29 Interventional | 2 | 45 | Cenicriviroc COVID-19 Covid19 | Despite multiple efforts, no further patient could be enrolled since 03/05/2021. A continuation
of the study is therefore no longer justified - | |||
| NCT04377503 Details | 2022-03-29 Interventional | 2 | 30 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… COVID-19 Cytokine Releas… Syndrome Covid-19 | The number of critically ill patients wirh COVID-19 decrease abruptly - | |||
| NCT03715166 2017-004419-38 Details | 2022-03-29 Interventional | 3 | 211 | Bumetanide Autism Spectrum… Autism Spectrum… | The 6-month efficacy analysis did not show any significant difference between bumetanide versus
placebo in the treatment of ASD in the overall studied population. No unexpected safety
concerns were identified. - | |||
| NCT02688790 NCT03617042 Details | 2022-03-29 Interventional | 1 | 8 | Dalbavancin Bacterial Infec… Communicable Di… Infections | - - | |||
| NCT04115956 Details | 2022-03-28 Interventional | 1 | 6 | Dexamethasone Melphalan Amyloidosis Immunoglobulin … AL Amyloidosis | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. - | |||
| NCT03259165 Details | 2022-03-28 Interventional | 2 | 51 | Diuretics Sodium Potassiu… Heart Failure Pulmonary Edema Acute Cardiac F… Acute Cardiac P… Heart Failure A… | COVID-19 pandemic. Initially had planned to resume study, but ultimately decided to close. - | |||
| NCT04464577 Details | 2022-03-25 Interventional | 1 | 0 | Bupropion Fluconazole Itraconazole Healthy Partici… | Business objectives have changed. - | |||
| NCT02992418 2019-003136-23 Details | 2022-03-25 Interventional | 3 | 688 | Vaccines Dengue Fever Hemorrhagic Fev… Hyperthermia Severe Dengue Dengue Fever Dengue Hemorrha… | No answer received from the Philippines Food and Drug Administration on protocol amendment
issued due to IDMC recommendations. CYD vaccine 3rd dose not given. Due to absence of response of competent authorities from The Philippines on protocol amendment, the study was prematurely terminated before injection of last dose (3rd dose) of the CYD dengue vaccine. Objectives related to 3rd dose were not assessed. | |||
| NCT03770299 2018-003719-23 Details | 2022-03-24 Interventional | 2 | 0 | Carboplatin Docetaxel Gemcitabine Nivolumab Paclitaxel Pemetrexed Vinorelbine Carcinoma, Non-… Lung Neoplasms Neoplasm, Resid… Circulating Tum… Non-Small Cell … Non-Small-Cell … | Business objectives have changed - | |||
| NCT02978716 2016-004466-26 Details | 2022-03-23 Interventional | 2 | 102 | Carboplatin Gemcitabine Breast Neoplasm… Neoplasms Triple Negative… Breast Cancer Breast Neoplasm Triple-Negative… Triple-Negative… | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety
concerns Limitations of this study are the small sample size and open-label design. Antitumor outcomes were not the primary endpoints. | |||
| NCT02212015 Details | 2022-03-22 Interventional | 2 | 26 | Paclitaxel Hemangiosarcoma Angiosarcoma | Due to interim analysis' results and definitions fixed in protocol - | |||
| NCT04529499 Details | 2022-03-21 Interventional | 3 | 353 | Favipiravir COVID-19 Covid19 | Study met pre-defined criteria for futility at interim analysis - |